EUVIMEDTutustu EUVIMEDiin
Systematische ÜbersichtOpen access · CC BY-NC 4.0

Effectiveness, safety and cost‐effectiveness of sacral neuromodulation for idiopathic slow‐transit constipation: a systematic review

Stella C M Heemskerk iD, Aart A van der Wilt iD, Bart M F Penninx, Jos Kleijnen iD, Jarno Melenhorst iD, Carmen D Dirksen iD, Stéphanie O Breukink iD

Colorectal Disease · 2024

DOI: 10.1111/codi.16876 ↗

At a glance

Systematische Übersicht in Colorectal Disease, 2024. Written by Stella C M Heemskerk and 6 co-authors. Institution: Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Center+, Maastricht, The Netherlands. Major MEDLINE topics: Constipation, Cost-Benefit Analysis, Electric Stimulation Therapy. Cited 12 times so far (Crossref); 48 references. The full text is freely available (open access, CC BY-NC 4.0).

TiivistelmäSubjectsBibliografiset tiedotCiteRelated studies

Abstract (original language)

Aim

Sacral neuromodulation (SNM) is a minimally invasive treatment option for functional constipation. Evidence regarding its effectiveness is contradictory, driven by heterogeneous study populations and designs. The aim of this study was to assess the effectiveness, safety and cost‐effectiveness of SNM in children and adults with refractory idiopathic slow‐transit constipation (STC).

Method

OVID Medline, OVID Embase, Cochrane Library, the KSR Evidence Database, the NHS Economic Evaluation Database and the International HTA Database were searched up to 25 May 2023. For effectiveness outcomes, randomized controlled trials (RCTs) were selected. For safety outcomes, all study designs were selected. For cost‐effectiveness outcomes, trial‐ and model‐based economic evaluations were selected for review. Study selection, risk of bias and quality assessment, and data extraction were independently performed by two reviewers. For the intervention ‘sacral neuromodulation’ effectiveness outcomes included defaecation frequency and constipation severity. Safety and cost‐effectiveness outcomes were, respectively, adverse events and incremental cost‐effectiveness ratios.

Results

Of 1390 records reviewed, 67 studies were selected for full‐text screening. For effectiveness, one cross‐over and one parallel‐group RCT was included, showing contradictory results. Eleven studies on safety were included (four RCTs, three prospective cohort studies and four retrospective cohort studies). Overall infection rates varied between 0% and 22%, whereas reoperation rates varied between 0% and 29%. One trial‐based economic evaluation was included, which concluded that SNM was not cost‐effective compared with personalized conservative treatment at a time horizon of 6 months. The review findings are limited by the small number of available studies and the heterogeneity in terms of study populations, definitions of refractory idiopathic STC and study designs.

Conclusion

Evidence for the (cost‐)effectiveness of SNM in children and adults with refractory idiopathic STC is inconclusive. Reoperation rates of up to 29% were reported.

Subjects

MeSH terms (MEDLINE)

ConstipationCost-Benefit AnalysisElectric Stimulation TherapyAdultChildFemaleHumansMaleMiddle AgedGastrointestinal TransitLumbosacral PlexusRandomized Controlled Trials as TopicSacrumTreatment Outcome

Author keywords

constipationcost‐effectivenesseffectivenesselectric stimulation therapysacral neuromodulationsafetyslow‐transit constipationsystematic review

Authors and institutions

  • Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Center+, Maastricht, The Netherlands.
  • Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands.
  • School of Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht University, Maastricht, The Netherlands.
  • Department of Surgery, Maastricht University Medical Center+, Maastricht, The Netherlands.
  • Kleijnen Systematic Reviews Ltd., York, UK.
  • School for Oncology and Reproduction (GROW), Maastricht University, Maastricht, The Netherlands.

ORCID profiles: Stella C M Heemskerk, Aart A van der Wilt, Jos Kleijnen, Jarno Melenhorst, Carmen D Dirksen, Stéphanie O Breukink

Cite

APA

Heemskerk, S. C. M., van der Wilt, A. A., Penninx, B. M. F., Kleijnen, J., Melenhorst, J., Dirksen, C. D., & Breukink, S. O. (2024). Effectiveness, safety and cost‐effectiveness of sacral neuromodulation for idiopathic slow‐transit constipation: a systematic review. Colorectal Disease. https://doi.org/10.1111/codi.16876

Vancouver

Heemskerk SCM, van der Wilt AA, Penninx BMF, Kleijnen J, Melenhorst J, Dirksen CD, et al. Effectiveness, safety and cost‐effectiveness of sacral neuromodulation for idiopathic slow‐transit constipation: a systematic review. Colorectal Disease. 2024. doi:10.1111/codi.16876

BibTeX
@article{Heemskerk2024,
  author = {Heemskerk, Stella C M and van der Wilt, Aart A and Penninx, Bart M F and Kleijnen, Jos and Melenhorst, Jarno and Dirksen, Carmen D and Breukink, Stéphanie O},
  title = {Effectiveness, safety and cost‐effectiveness of sacral neuromodulation for idiopathic slow‐transit constipation: a systematic review},
  journal = {Colorectal Disease},
  year = {2024},
  doi = {10.1111/codi.16876}
}
Start for free →